Alternatives to hormone therapy for hot flashes: Many choices but science is lacking

Menopause

Volumn 20, Issue 9, 2013, Pages 980-982

  Richardson, Marcie K ^a,b  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONIDINE; DESVENLAFAXINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FOLIC ACID; GABAPENTIN; GESTAGEN; MAGNESIUM OXIDE; PAROXETINE; PREGABALIN; SERADA; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; SOYBEAN PROTEIN;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CASE REPORT; CLIMACTERIUM; DIZZINESS; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MENSTRUAL CYCLE; NAUSEA; RELAXATION TRAINING; SEXUAL DYSFUNCTION; SHIVERING; SKIN CONDUCTANCE; SOCIAL PSYCHOLOGY; SWEATING; DIET SUPPLEMENTATION; HEALTH BEHAVIOR; HEALTH STATUS; HOT FLASHES; MENOPAUSE; MIDDLE AGED; PHYSIOLOGY; PHYTOTHERAPY; PROCEDURES;

DIETARY SUPPLEMENTS; FEMALE; HEALTH BEHAVIOR; HEALTH STATUS; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PHYTOTHERAPY; SOYBEAN PROTEINS;

EID: 84883656071     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e3182982436     Document Type: Article

References (24)

1. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193.
2. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric 2011;14:515-528.
3. Mann E, Hunter S. Concordance between self-reported and sternal skin conductance measures of hot flushes in symptomatic perimenopausal and post-menopausal women: a systematic review. Menopause 2011;18:709-722.
4. Thurston RC, Bromberger JT, Joffe H, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause 2008;15:841-847.
5. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095-1104.
6. Rödström K, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelundi C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;9:156-161.
7. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health Across the Nation. Obstet Gynecol Clin North Am 2011;38:489-501.
8. Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatmentVeffectiveness for severe vasomotor symptoms and lack of withdrawal rebound. Gynecol Endocrinol 2012;28(suppl 2):7-11.
9. Innes KE, Selfe TK, Vishnu A. Mind-body therapies for menopausal symptoms: a systematic review. Maturitas 2010;66:135-149.
10. Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011;71:287-304.
11. Gaweesh SS, Abdel-Gawad MM, Nagaty AM, Ewies AA. Folic acid supplementation may cure hot flushes in postmenopausal women: a prospective cohort study. Gynecol Endocrinol 2010;26:658-662.
12. Park H, Parker GL, Boardman CH, Morris MM, Smith TJ. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer 2011;19:859-863.
13. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial JAMA 2003;289:2827-2834.
14. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, doubleblind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. Clin Oncol 2010;28:641-647.
15. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010;CD004923.
16. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-48.
17. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebocontrolled trial. Lancet 2005;366:818-824.
18. Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RJ. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause 2013;20:38-46.
19. Suvanto-Luukkonen E, Koivunen R, Sundström H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18-26.
20. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011; 29:3862-3868.
21. Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol 2011;29:3842-3846.
22. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-2837.
23. Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 2007; 14:841-845.
24. Joffe H, Guthrie KA, Larson J, et al. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network. Menopause 2013;20:261-268.